What happened with RCUS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Arcus Biosciences is advancing cancer medicines through clinical trials, including late-stage studies, while its inflammation and autoimmune programs are still in research and preclinical development. None of its investigational products is approved for sale, and it has never earned revenue from product sales.
Drug-company partners pay Arcus for access to its pipeline, licenses and development work through upfront payments, milestones and research support. Licensing and development services provide most revenue, and Gilead accounts for almost all of it; Taiho is another partner. Arcus depends heavily on Gilead to help develop and commercialize the programs Gilead licenses, and Gilead’s option rights limit Arcus’s ability to arrange other collaborations.
If products gain regulatory approval, Arcus could earn royalties from partner sales and share profits and losses on programs it co-promotes with Gilead in the United States. It retains rights to casdatifan outside Taiho’s territory of Japan and certain other Asian countries excluding China, and plans to build U.S. commercial capabilities if registrational trials succeed. Arcus also relies on outside manufacturers for drug supplies, with each investigational product expected to depend on a single supplier for the foreseeable future.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Arcus Biosciences’ results hinge on trial outcomes and partner commitments, including Taiho’s licensing and development arrangements in Japan and certain other Asian markets excluding China.
Arcus depends heavily on Gilead Sciences, which pays for rights to its cancer programs and co-develops them; Gilead accounted for 97% of Arcus’s 2025 revenue. Watch Gilead’s commitments to these programs, where the partners generally share global development costs equally, subject to Arcus’s opt-out rights and spending limits.
Merck’s approved belzutifan competes directly with Arcus’s casdatifan opportunity in advanced renal cell carcinoma. Merck sells prescription medicines to wholesalers, hospitals and other healthcare buyers; belzutifan’s results in this patient group are the relevant comparison for Arcus’s kidney-cancer candidate.
AstraZeneca both competes with Arcus’s cancer-immunotherapy combinations through rilvegostomig, which targets TIGIT and PD-1, and works with Arcus on eVolve-RCC02. The companies temporarily paused enrollment after potential immune-mediated adverse events, making safety updates from that trial directly relevant to Arcus’s development plans.
Arcus’s TIGIT trial news reaches Compugen’s partnering prospects: Compugen says negative results, including Arcus and Gilead’s STAR-221 futility stop, hurt COM902’s development and revenue potential. Compugen earns partner payments by licensing cancer candidates, including the competing rilvegostomig program to AstraZeneca; watch whether further TIGIT data change its decision not to start new COM902 trials.
Revolution Medicines’ daraxonrasib competes with Arcus’s quemliclustat to improve treatment of metastatic pancreatic cancer, with both candidates in late-stage development. Revolution develops targeted cancer drugs and reported no collaboration revenue in 2025; daraxonrasib’s trial results, rather than current revenue, are the comparison to watch for Arcus.
Novartis is developing small-molecule drugs targeting HIF-2α that could compete with Arcus’s casdatifan in kidney cancer. Novartis sells prescription medicines across several disease areas, but progress in these kidney-cancer candidates is the news most relevant to Arcus.
Bristol Myers Squibb’s Opdivo-based treatment regimens compete with Arcus’s prospective kidney-cancer treatments and combinations that target immune checkpoints.
Corvus Pharmaceuticals’ ciforadenant and Arcus’s etrumadenant compete by targeting adenosine signaling in cancer, while both companies also develop inflammatory-disease treatments. Corvus has no approved products or product-sales revenue; watch ciforadenant’s trial with ipilimumab and nivolumab as first-line treatment for metastatic renal cell carcinoma.
Agenus’s botensilimab/balstilimab cancer-immunotherapy combination competes with Arcus’s PD-1-based combination strategy. Agenus began earning revenue from this treatment through authorized access programs in the second half of 2025, but that access does not constitute marketing approval.
Arcus Biosciences, Inc. earningsThis company
Arcus Biosciences has no product sales, so this report shows how partner-funded work and development spending shape its revenue and cash runway.
Read collaboration revenue alongside cash used in operations, and note which partners and obligations drive the revenue: ongoing development services or completed license obligations. Revenue backed by continuing work with slower cash use would show partners are still supporting the pipeline. Falling revenue, or revenue driven mainly by recognition timing, alongside faster cash use would show that reported revenue is not recurring product sales and development relies more on partner payments or financing.
Fed Interest Rate Decision
Arcus’s Fed interest-rate decision matters because it can move the prime-based rate on its $100 million Hercules loan, changing the cash interest Arcus pays and leaving less or more money for drug development.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s policy rate comes in above the estimate, higher rates may raise the prime-based loan rate and Arcus’s cash interest costs, leaving less funding for its clinical programs.
If it comes in below expectations
If the Fed’s policy rate comes in below the estimate, lower rates may reduce the prime-based loan rate and Arcus’s cash interest costs, leaving more funding for its clinical programs.
Gilead Sciences Inc earningsGILD
Gilead Sciences’ report shows whether it is continuing to fund shared cancer programs, which affects Arcus Biosciences’ development costs and pace.
Look for Gilead’s development spending and progress on shared programs, alongside Arcus’s collaboration revenue and operating cash use. Continued investment would show Gilead is still sharing the development burden; a pullback could leave Arcus carrying more cost or slowing programs, especially given its heavy revenue dependence on Gilead.
Merck & Co., Inc. earningsMRK
Merck’s report can show how its approved belzutifan is doing in advanced kidney cancer, a commercial benchmark for Arcus Biosciences’ investigational casdatifan.
Look for Merck’s account of belzutifan’s use or sales in advanced kidney cancer. Strong demand would show an incumbent treatment has established a foothold that casdatifan would have to overcome if approved; weaker demand could leave room, but Arcus would still need to prove its candidate works, is safe and wins approval.
AstraZeneca PLC earningsAZN
AstraZeneca’s report may update safety in its eVolve-RCC02 study with Arcus Biosciences, showing whether their kidney-cancer trial can move ahead.
Watch whether the potential immune-mediated adverse events are clarified and whether enrollment resumes. A manageable safety picture and resumed enrollment would support continued testing of the combination; unresolved risks and a continued pause would delay Arcus’s kidney-cancer program and could force changes to the study.
